CA2271799A1 - Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes - Google Patents

Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes Download PDF

Info

Publication number
CA2271799A1
CA2271799A1 CA002271799A CA2271799A CA2271799A1 CA 2271799 A1 CA2271799 A1 CA 2271799A1 CA 002271799 A CA002271799 A CA 002271799A CA 2271799 A CA2271799 A CA 2271799A CA 2271799 A1 CA2271799 A1 CA 2271799A1
Authority
CA
Canada
Prior art keywords
bismuth
days
milligrams
composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271799A
Other languages
English (en)
Inventor
Jonathan Davidson Kaunitz
Owen Rickford Carryl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of CA2271799A1 publication Critical patent/CA2271799A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des méthodes et des compositions pour traiter les troubles gastro-intestinaux provoqués par Helicobacter pylori, contenant du bismuth, une quantité gastropathique d'un médicament anti-inflammatoire non stéroïdien et une quantité suffisante pour avoir un effet thérapeutique d'un ou de plusieurs anti-microbiens. La composition peut également contenir une quantité suffisante pour avoir un effet thérapeutique, d'un ou de plusieurs médicaments anti-sécrétoires.
CA002271799A 1996-11-22 1997-11-21 Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes Abandoned CA2271799A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75551896A 1996-11-22 1996-11-22
US08/755,518 1996-11-22
PCT/US1997/021461 WO1998022117A1 (fr) 1996-11-22 1997-11-21 Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodes correspondantes

Publications (1)

Publication Number Publication Date
CA2271799A1 true CA2271799A1 (fr) 1998-05-28

Family

ID=25039486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271799A Abandoned CA2271799A1 (fr) 1996-11-22 1997-11-21 Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes

Country Status (4)

Country Link
EP (1) EP0941101A1 (fr)
CA (1) CA2271799A1 (fr)
NO (1) NO992469L (fr)
WO (1) WO1998022117A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
WO1999010000A1 (fr) * 1997-08-25 1999-03-04 The Procter & Gamble Company Preparations combinees pour le traitement des douleurs du tractus gastro-intestinal superieur
IL145220A0 (en) * 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
IL142037A0 (en) * 2001-03-15 2002-03-10 Agis Ind 1983 Ltd Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6926907B2 (en) 2001-06-01 2005-08-09 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
JP5035865B2 (ja) * 2005-09-26 2012-09-26 国立大学法人高知大学 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ菌株の増殖・運動抑制方法
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CA2900763C (fr) 2013-02-13 2021-04-06 Reza Fathi Compositions pharmaceutiques destinees au traitement d'helicobacter pylori
US11096948B2 (en) * 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI910088A (fi) * 1990-01-09 1991-07-10 Gist Brocades Nv Oral farmaceutisk komposition.
DK0550083T3 (da) * 1991-12-06 1999-10-11 Glaxo Group Ltd Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra

Also Published As

Publication number Publication date
NO992469L (no) 1999-07-22
NO992469D0 (no) 1999-05-21
EP0941101A1 (fr) 1999-09-15
WO1998022117A1 (fr) 1998-05-28

Similar Documents

Publication Publication Date Title
CA2271799A1 (fr) Compositions de traitement de troubles gastro-intestinaux contenant du bismuth, des anti-inflammatoires non steroidiens ainsi qu'un ou plusieurs agents anti-microbiens et methodescorrespondantes
EP0941102A1 (fr) Compositions et methodes pour traiter des troubles gastro-intestinaux
Malfertheiner et al. Helicobacter pylori: perspectives and time trends
JPH0794390B2 (ja) 胃腸疾患の治療のための医薬組成物
JP5908569B2 (ja) 胃腸疾患を治療するための方法
EP0206626B1 (fr) Utilisation de bismuth pour la fabrication d'un médicament destiné au traitement des désordres gastrointestinaux dûs à Campylobacter polyridis
Lane et al. Recurrence of duodenal ulcer after medical treatment
US5407688A (en) Compositions and methods for treating gastrointestinal disorders
US5403830A (en) Compositions and methods of treating gastrointestinal disorders
Graham et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole.
Holle Pathophysiology and modern treatment of ulcer disease
EP2705845A1 (fr) Combinaison de sel de zinc et d'agent anti-h pilori comme inhibiteur à action rapide de la sécrétion d'acide gastrique
US5447923A (en) Methods and compositions of diphenyl ether phosphate esters for the treatment of gastrointestinal disorders
US4940695A (en) Bismuth-containing pharmaceutical compositions
Porro et al. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone.
Dooley Helicobacter pylori: review of research findings
JP2669818B2 (ja) 胃腸障害の治療及び予防のためのニトロフラントインの使用
WO1996024342A1 (fr) Traitement concomitant a base de composes au bismuth par voie orale
Ansorg et al. Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs
JP2006506409A (ja) 合成ラクトン処方物ならびに方法および使用
CA2239420C (fr) Compositions destinees a la prevention et au traitement de troubles gastro-intestinaux et comprenant du bismuth ainsi qu'un ou plusieurs agents antimicrobiens
Graham et al. Omeprazole as an adjuvant to antimicrobial therapy for eradication of Helicobacter pylori infection
Dahlgren et al. Organobismuth compounds: activity against Helicobacter pylori
Tafaj et al. Acute Esophageal Necrosis. A Case Report.
Furukawa et al. Low-dose aspirin delays gastric healing after Helicobacter pylori eradication

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued